Goldman initiated coverage on Amneal Pharmaceuticals with a new price target
$AMRX
Biotechnology: Pharmaceutical Preparations
Health Care
Goldman initiated coverage of Amneal Pharmaceuticals with a rating of Buy and set a new price target of $12.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/6/2025 | $12.00 | Buy | Goldman |
| 2/24/2025 | $9.00 → $12.00 | Neutral → Overweight | Analyst |
| 9/6/2024 | $9.00 | Underweight → Neutral | JP Morgan |